Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eli Lilly and Company (NYSE: LLY) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents help investors understand Lilly’s capital structure, governance, financing activities and material events affecting the business.
Lilly’s common stock and several series of notes are registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the New York Stock Exchange, including common stock under the symbol LLY and multiple note series with maturities ranging from 2026 to 2061. Recent Form 8-K filings disclose items such as quarterly financial results furnished under Item 2.02, other events under Item 8.01, and governance changes under Item 5.02. For example, an August 2025 Form 8-K describes an underwriting agreement for floating-rate notes due 2028 and fixed-rate notes due between 2028 and 2065, while a November 2025 Form 8-K reports the election of a new independent director to Lilly’s board.
Through this page, users can review current and historical 8-Ks, along with other core filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q when available. These filings typically include details on Lilly’s therapeutic focus areas—such as cardiometabolic health, obesity, oncology, immunology and neuroscience—its risk factors, research and development programs, and financial condition.
Stock Titan enhances access to Lilly’s filings by pairing real-time EDGAR updates with AI-powered summaries. AI-generated overviews can help explain the significance of complex documents, such as new debt offerings, governance changes or major transactions, in plain language. Users can also quickly identify insider and executive-related disclosures when they appear in Forms 3, 4 or 5, and track how financing decisions, such as multi-series note issuances, fit into Lilly’s broader capital strategy.
Whether you are analyzing LLY’s latest 10-K, reviewing 10-Q trends, or examining 8-Ks related to acquisitions, collaborations and manufacturing investments, this filings hub offers a structured view of the company’s regulatory record with tools to make dense disclosures easier to interpret.
Juan R. Luciano, a director of Eli Lilly & Co (LLY), reported a non-derivative acquisition on 09/15/2025. The filing shows an acquisition of 19.826 shares (reported with a price of $748.19 per share) and indicates 16,455.857 shares beneficially owned following the transaction in a direct ownership form. The filing explains these shares were deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in common stock after the reporting person’s separation from service. The Form 4 was signed on behalf of Mr. Luciano on 09/17/2025 by an authorized filer.
Mary Lynne Hedley, a director of Eli Lilly & Co. (LLY), reported an internal acquisition of common stock on 09/15/2025. The filing shows 2,003.492 shares were acquired and recorded as deferred stock units under the Lilly Directors' Deferral Plan, to be settled in shares following the reporting person's separation from service. The report lists a per-share amount of $748.19 associated with the transaction. The reporting person disclaims beneficial ownership except to the extent of a pecuniary interest, noting the shares are held by a trust. The Form 4 was signed on behalf of Hedley by Jonathan Groff on 09/17/2025.
J. Erik Fyrwald, a director of Eli Lilly & Co. (LLY), reported an acquisition on 09/15/2025 of 74,751.392 shares of common stock. The Form 4 lists a per-share price of $748.19. The filing explains these shares were elected to be deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person’s separation from service. The report is signed on behalf of Fyrwald on 09/17/2025.
Ralph Alvarez, a director of Eli Lilly & Co (LLY), reported a non-derivative acquisition on 09/15/2025. The filing shows an acquisition of 15.705 common stock units at a reported price of $748.19, and after the transaction the reporting person is shown as beneficially owning 55,137.85 shares (direct) and 758 shares indirectly through a trust. The filing discloses these shares were deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in common stock following the reporting person’s separation from service. The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest.
Edgardo Hernandez, EVP & President, Manufacturing Operations at Eli Lilly & Co. (LLY), reported changes in ownership on a Form 4. On 09/05/2025 he disposed of 17 shares of Eli Lilly common stock in a transaction coded G at a price of $0. After the reported disposition he directly beneficially owned 39,731.435 shares and indirectly held 872.3 shares through a 401(k). No derivative securities were reported. The form was signed on behalf of Mr. Hernandez on 09/08/2025.
Form 144 notice for Eli Lilly & Co. (LLY) reports a proposed sale of 2,000 common shares through Morgan Stanley Smith Barney LLC on 08/28/2025 on the NYSE with an aggregate market value of $1,468,340.00. The shares were acquired as Restricted Stock Units on 02/09/2022 from the issuer and payment information is listed as N/A.
The filer reports no securities sold during the past three months. The form includes the standard representation that the selling person is not aware of undisclosed material adverse information and provides space for signature and plan-adoption dates, but those fields are not populated in the supplied content.
Kenneth L. Custer, EVP & President, Card Met Hlth at Eli Lilly & Co (LLY), reported insider transactions dated 08/27/2025 and filed 08/28/2025. The filing shows a disposition of 9,346.902 shares of Eli Lilly common stock. It also reports a reallocation within the reporting person's deferred compensation account resulting in 612.937 shares of phantom stock (payable in cash after employment termination). After the reported transactions, the filing states the reporting person beneficially owns 2,173.461 shares of common stock. The form is signed on behalf of Mr. Custer by an authorized representative.
Donald A. Zakrowski, Senior Vice President, Finance & Chief Accounting Officer at Eli Lilly & Co. (LLY), reported a sale of 1,000 shares of Eli Lilly common stock on 08/28/2025 at a price of $734.93 per share. The filing states the sale was executed under a Rule 10b5-1 trading plan adopted on November 20, 2024. After the transaction, the reporting person beneficially owned 3,839.659 shares directly and 1,725.72 shares indirectly (401(k)). The Form 4 was signed by an authorized representative on behalf of Mr. Zakrowski.
Eli Lilly & Company filed an 8-K disclosing documentation related to a debt offering. The filing includes an Underwriting Agreement dated August 18, 2025, an Indenture (originally dated February 1, 1991) and a Tripartite Agreement appointing Deutsche Bank Trust Company Americas as successor trustee. The exhibits provide forms of Fixed Rate and Floating Rate Notes, including a Floating Rate Note due 2028 and fixed-rate notes with stated coupons of 4.000% (2028), 4.250% (2031), 4.550% (2032), 4.900% (2035), 5.550% (2055) and 5.650% (2065). Legal opinions by Kirkland & Ellis LLP and Jamie Burnett, Esq., and their consents are included, as well as a Cover Page Interactive Data File. The filing is signed by Jon Haug, Senior Vice President, Treasurer and Corporate Finance and Investment Banking, dated August 20, 2025.
Gabrielle Sulzberger, a director of Eli Lilly & Co. (LLY), reported an acquisition of 2,710.158 shares of common stock on 08/18/2025. The filing shows the shares were acquired at a price of $698.05 and, at the reporting person’s election, have been deferred as stock units under the Lilly Directors' Deferral Plan. Those units will be settled in shares of common stock following the reporting person’s separation from service. The Form 4 was signed and submitted on 08/19/2025.